Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in Advanced TNBC Irrespective of PD-L1 Expression By Ogkologos - July 16, 2025 737 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATRACTIB study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Tackling under-representation of Black data scientists in cancer research November 7, 2022 When Natural Disasters Strike, This Program Helps Provide Relief To People... October 3, 2019 Can a Biopsy Make My Cancer Spread? March 18, 2021 ‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges... June 23, 2022 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Head and Neck Cancer and... RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and... Cancer in My Community: Overcoming Inequities in Care in Argentina
